Skip to main content

Rina Wolf

Genomind has appointed Rina Wolf to its board. She is vice president of commercialization strategies, consulting, and industry affairs at Xifin. Prior to Xifin, Wolf was an executive with commercialization and reimbursement responsibilities at several firms, including Genomic Health, RedPath Integrated Pathology, and Esoterix, now part of Laboratory Corporation of America.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.